Srebf1 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| **SREBF1 Gene** | |
|---|---|
| **Full Name** | Sterol Regulatory Element Binding Transcription Factor 1 |
| **Symbol** | SREBF1 (SREBP1) |
| **Chromosome** | 17p11.2 |
| **NCBI Gene ID** | 6720 |
| **OMIM** | 184756 |
| **Ensembl ID** | ENSG00000172318 |
| **UniProt** | P36956 |
| **Associated Diseases** | Alzheimer's Disease, Parkinson's Disease, Metabolic Syndrome, Fatty Liver Disease, Huntington's Disease, ALS |
The SREBF1 gene (commonly known as SREBP1) encodes sterol regulatory element-binding protein 1, a critical transcription factor that regulates lipid metabolism and cellular energy homeostasis. SREBP1 serves as the master regulator of fatty acid and triglyceride synthesis, controlling genes involved in lipogenesis, cholesterol biosynthesis, and lipid droplet formation. Beyond its well-established role in metabolic diseases, SREBP1 has emerged as an important player in neurodegenerative disorders, where lipid dysregulation contributes to disease pathogenesis.
SREBP1 belongs to the SREBP family of transcription factors:
Isoform
Gene
Function
Tissue Expression
SREBP1a
SREBF1
Strong activator, full-length
Widely expressed
SREBP1c
SREBF1
Insulin-regulated isoform
Liver, adipose, brain
The SREBP1 gene produces multiple transcripts through alternative splicing:
SREBP1a : More potent transcription factor, wider target gene rangeSREBP1c : Primarily regulates fatty acid synthesis, insulin-responsive
SREBP1 contains several functional domains:
N-terminal transcription activation domain - Transactivates target genesSterol-sensing domain - Responds to sterol levelsBasic-helix-loop-helix-leucine zipper (bHLH-LZ) - DNA bindingC-terminal regulatory domain - Interactions with SCAP and INSIG
SREBP1 controls the expression of genes involved in:
Fatty Acid Synthesis :
ACC (Acetyl-CoA carboxylase)
FAS (Fatty acid synthase)
SCD1 (Stearoyl-CoA desaturase)
Triglyceride Synthesis :
GPAT (Glycerol-3-phosphate acyltransferase)
DGAT (Diacylglycerol acyltransferase)
Cholesterol Synthesis :
HMG-CoA reductase (rate-limiting)
HMG-CoA synthase
Squalene synthase
Beyond lipid synthesis, SREBP1 regulates:
ER stress response - Links lipid metabolism to unfolded protein response Autophagy Inflammation - NF-κB signaling modulationCell growth - Coordinates lipid availability with proliferation
Insulin signaling : PI3K/Akt pathway activates SREBP1cGlucose : ChREBP cooperationLeptin : Negative regulationGlucocorticoids : Activation
Proteolytic cleavage : SCAP-mediated ER to Golgi traffickingSterol feedback : Cholesterol levels control maturationPhosphorylation : mTOR and AMPK modify activityUbiquitination : Protein stability control
SREBP1 is expressed throughout the brain:
Cerebral cortex - High neuronal expressionHippocampus Cerebellum - Purkinje cellsHypothalamus - Metabolic regulationSubstantia nigra - Dopaminergic neuronsStriatum - Medium spiny neurons
Neurons Astrocytes Oligodendrocytes : Myelin lipid synthesisMicroglia
SREBP1 dysregulation is prominent in AD:
Lipid Metabolism Abnormalities :
Altered brain cholesterol homeostasis
Changed fatty acid composition
Lipid droplet accumulation in glia
Amyloid Processing :
SREBP1 affects APP processing
Altered γ-secretase activity
Aβ -induced lipotoxicity
Therapeutic Implications :
SREBP1 modulators under investigation
Diet interventions affect SREBP1
Statins have indirect effects
SREBP1 involvement in PD:
α-Synuclein interactionMitochondrial function : Lipid composition affects respirationNeuroinflammation : SREBP1 modulates glial activationDopaminergic vulnerability : Lipid homeostasis critical
SREBP1 dysfunction in HD:
Transcriptional dysregulation : Mutant huntingtin affects SREBP1Metabolic abnormalities : Lipid metabolism alteredTherapeutic target : SREBP1 modulation may help
Lipid metabolism in motor neuronsEnergy homeostasis disruptionLipid droplet accumulation
SREBP1 hyperactivity contributes to:
Obesity : Increased lipogenesisFatty liver : Hepatic lipid accumulationInsulin resistance : Lipid intermediates interfere with signalingDyslipidemia : Elevated triglycerides
Approach
Compound
Mechanism
Status
SREBP1 inhibitor
Fatostatin
Prevents cleavage
Preclinical
SREBP1 inhibitor
Betulin
Blocks maturation
Preclinical
Statins
Simvastatin
Indirect reduction
Approved
Farnesoid X receptor agonists
Obeticholic acid
FXR-SREBP1 axis
Approved for PBC
Calorie restriction : Reduces SREBP1 activityKetogenic diet : Alternative energy substrateExercise : Improves insulin sensitivityOmega-3 fatty acids : Counteracts dyslipidemia
Gene therapy : Targeted deliveryAntisense oligonucleotides : SREBP1 knockdownCRISPR editing : Epigenetic modulation
ChIP-seq : Genome-wide binding analysisRNA-seq : Transcriptomic profilingLipidomics : Comprehensive lipid analysisProteomics : Protein interaction studiesMetabolomics : Metabolic pathway analysis
SREBP1 knockout : Embryonic lethal (SREBP1a), viable (SREBP1c)Conditional knockouts : Tissue-specific deletionTransgenic overexpression : Lipid accumulation models
The study of Srebf1 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.